The First Clinical Trials Conducted at NSU Medical Center

Cognitive disorders are one of the most urgent problems in modern medicine. Severe disorders of cognitive functions disrupt everyday social and professional activities and lead to a decrease in the quality of life. The greatest concern is caused by dementia and a special clinical form of cerebrovascular pathology, cerebral ischemia, that has a tendency to develop at a younger age. On April 29, the Medical Research and Education Center at the NSU V. Zelman Institute of Medicine and Psychology (NSU ZIMP) began conducting clinical trials for polypeptide tissue-specific drugs of animal origin that are used to regulate and restore brain activity in cerebral ischemia and dementia. 

Nina Dolgova, Director of the NSU Medical Center and Senior Lecturer at NSU ZIMP talked about the trial, 

The main goal of clinical research is to find the best way to prevent, diagnose, and treat a particular disease. Conducting clinical research is necessary for the development of medicine, increasing the availability of new methods of treatment, and improving the quality of life for people. We are pleased to start a clinical study on the therapeutic equivalence of Corencef compared to Cortexin, which is used to improve the processes of memorization and retrieval of memory, stimulate DNA repair processes in the brain, and accelerate the recovery of brain functions after stressful effects and ischemia. 

The comparison of Corencef and Cortexin will be conducted by highly qualified specialists with extensive experience in practical medicine. 

Andrey Pokrovsky, Director of NSU ZIMP provided some background,

We have been trying to conduct this type of work for a long time because it is multifaceted. First, there are the actual clinical trials. After that comes the training of personnel, doctors and students, to know how to properly conduct this research. A special mini-course on conducting clinical trials was organized for students. The third component is the publication of the results of our work in highly rated journals. Future plans include work on 7 drugs, the most important and interesting of which is a vaccine against human papillomavirus. It is no secret that certain strains and types of this virus are the cause of the development of cervical cancer, skin cancer, and other oncologies. Since the mid-2000s, this vaccination has been mandatory for young people in Europe and the United States. It is assumed that the clinical trials for this vaccine will be at our Institute. 

To conduct tests of a new drug, the NSU Institute of Science and Technology invites volunteers aged 40 to 85 years who suffer from stage I-II cerebral ischemia and who have not taken neuroprotective drugs, nootropic drugs, antioxidants, and drugs with tissue-specific effects on nervous tissue over the past month. The design of the study involves voluntary consent, mandatory health insurance for each patient, and the ability to withdraw from the study at any time.

Dolgova added,

Unfortunately, for a number of reasons, the most modern drugs become available for use in medical practice much later than data on their high efficiency appears. Since the drug under study can potentially be more effective than standard methods, participation in a clinical trial is an opportunity for volunteers to receive modern treatment that is not currently available in the context of conventional medical practice.